With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

Kinvard Bio is creating a new class of antibiotics to treat drug-resistant infections and diseases.

Scientists zoom in on microbial messages at the molecular level to understand how the microbiome shapes health.

Sponsored research agreement between Harvard and Roche resulted in the Kahne Lab’s discovery of the mechanism of action for Roche’s compound, paving the way for the development of new antibiotics.